Literature DB >> 9926300

The role of partial splenectomy in children with thalassemia.

A H al-Salem1, I al-Dabbous, P Bhamidibati.   

Abstract

Partial splenectomy was performed on 12 patients with thalassemia (9 beta-thalassemia major and 3 Hb H disease) to reduce blood transfusion requirements. The indication for partial splenectomy was the presence of splenomegaly and increased blood transfusion requirements (i.e. Hb drop > 0.5 g per week). Their ages ranged from 3 to 10 years (mean 6.9 years). On follow-up, ranging from 1.1-5.5 years (mean 2.6 years), two of the three patients with Hb H disease required no more blood transfusions while the third continued to receive blood transfusions, but at a lower frequency. For those with beta-thalassemia major, the transfusion requirements and Hb drop per week decreased in the majority of patients. This is specially so during the first 1-2 years following partial splenectomy. In all, about 1/3 of the size of the normal spleen was preserved (either upper or lower pole) which was judged functional as there has been no significant infection in any of the patients, no change in IgM level, no Howell-Jolly bodies and visualization on scintigraphy. Partial splenectomy is recommended to start with for those with Hb H disease. For patients with beta-thalassemia major, partial splenectomy is beneficial as a temporary measure and in those children who are less than 5 years of age, as they are at greater risk of post splenectomy sepsis.

Entities:  

Mesh:

Year:  1998        PMID: 9926300     DOI: 10.1055/s-2008-1071227

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  2 in total

1.  Pediatric splenectomy for hematological diseases: outcome analysis.

Authors:  C U Durakbasa; C Timur; V Sehiralti; M Mutus; N Tosyali; A Yoruk
Journal:  Pediatr Surg Int       Date:  2006-07-13       Impact factor: 1.827

2.  Splenectomy for people with thalassaemia major or intermedia.

Authors:  Akshay Sharma; Manu Easow Mathew; Latika Puri
Journal:  Cochrane Database Syst Rev       Date:  2019-09-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.